Cladribine with Low-Dose Cytarabine

Phase II Prospective Randomized Control Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

More Information

Trial Status
Not yet accepting
Trial Phase
Phase 2
Enrollment
98 patients (estimated)
Sponsors
Shands Hospital
Tags
Chemotherapy, Randomization
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1992
NCT Identifier
NCT05766514

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.